Comparing Pazopanib vs Sunitinib
| Pazopanib Remove Pazopanib from your drug comparison | Sunitinib Remove Sunitinib from your drug comparison |
|---|
| Pazopanib Remove Pazopanib from your drug comparison | Sunitinib Remove Sunitinib from your drug comparison | |
|---|---|---|
|
Prescribed for Soft Tissue Sarcoma, Renal Cell Carcinoma. pazopanib may also be used for purposes not listed in this medication guide. |
Prescribed for Gastrointestinal Stromal Tumor, Renal Cell Carcinoma, Pancreatic Cancer. sunitinib may also be used for purposes not listed in this medication guide. |
|
|
Prescription only |
Prescription only |
|
Ratings & Reviews |
||
Drug Class |
||
Side Effects |
||
|
Commonly reported side effects include: bleeding tendency disorder, abdominal pain, decreased serum glucose, decreased serum magnesium, decreased serum phosphate, diarrhea, fatigue, hypertension, increased serum alanine aminotransferase, increased serum aspartate aminotransferase, increased serum bilirubin, leukopenia, nausea, neutropenia, thrombocytopenia, vomiting, and anorexia. See the full pazopanib side effects document. |
Commonly reported side effects include: oral candidiasis, asthenia, decreased left ventricular ejection fraction, diarrhea, hypokalemia, lymphocytopenia, mucositis, neutropenia, vomiting, and hypertension. See the full sunitinib side effects document. |
|
Pricing and Coupons* Prices are without insurance |
||
|
We could not find an exact match for this medicine. Try searching the Price Guide directly. |
We could not find an exact match for this medicine. Try searching the Price Guide directly. |
|
Generic Availability |
||
|
No |
No |
|
Dosage Form(s) Available |
||
| N/A | N/A | |
Brand Names |
||
| Votrient | Sutent | |
Half LifeThe half-life of a drug is the time taken for the plasma concentration of a drug to reduce to half its original value. |
||
|
30.9 hours |
60 hours |
|
CSA Schedule**View glossary of terms. |
||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
|
Pregnancy Category |
||
|
Category D
Positive evidence of risk
See the full Pregnancy Warnings document. |
Category D
Positive evidence of risk
See the full Pregnancy Warnings document. |
|
FDA Alerts |
||
|
N/A |
N/A |
|
Drug Interactions |
||
|
A total of 554 drugs are known to interact with pazopanib:
|
A total of 398 drugs are known to interact with sunitinib:
|
|
Alcohol/Food/Lifestyle Interactions |
||
|
|
|
Disease Interactions |
||
First Approval Date |
||
|
October 19, 2009 |
January 26, 2006 |
|
WADA ClassView World Anti-Doping Agency classifications. |
||
|
N/A |
N/A |
|
More Information |
||
Consumer Resources |
||
Professional Resources |
||
Related Treatment Guide |
||
** The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.